GlassScriptPhysician profile
Michael J Dimitrion
NPI 1508878836
$5,934.84
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,352 · 2020: $1,362 · 2021: $1,256 · 2022: $837 · 2023: $594 · 2024: $533.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,118 · Education: $8.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,118.30 |
| Education | $8.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,074.83 | 2019-2024 | Airsupra, Farxiga |
| Novo Nordisk INC | $1,042.49 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Sanofi-Aventis U.S. LLC | $1,002.47 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $390.00 | 2019-2024 | Jardiance |
| Lilly USA, LLC | $373.85 | 2019-2023 | Jardiance, Emgality |
| Abbvie INC. | $354.65 | 2021-2024 | Ubrelvy |
| Amarin Pharma, INC. | $350.30 | 2020-2023 | |
| Glaxosmithkline, LLC. | $238.55 | 2020-2024 | Trelegy Ellipta |
| Horizon Therapeutics Plc | $220.60 | 2019-2022 | |
| Pfizer INC. | $214.76 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $203.96 | 2023-2024 | |
| Amgen INC. | $80.03 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $72.47 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $46.61 | 2019-2020 | |
| Radius Health, INC. | $41.94 | 2019-2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $39.25 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $27.98 | 2023 | Rexulti |
| Gilead Sciences, INC. | $27.31 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $24.29 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $21.38 | 2020 | |
| Genentech USA, INC. | $19.72 | 2020 | |
| Janssen Pharmaceuticals, INC | $19.26 | 2019 | |
| Novartis Pharmaceuticals Corporation | $19.06 | 2019 | |
| Ironwood Pharmaceuticals, INC | $17.37 | 2020 | |
| Boston Scientific Corporation | $11.71 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Dimitrion listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.